Experimental cocktail targets Hard-to-Treat lymphoma

NCT ID NCT05626322

Terminated Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tested a combination of three drugs—maplirpacept, tafasitamab, and lenalidomide—in 6 people with diffuse large B-cell lymphoma (DLBCL) that had returned or not responded to prior treatment. Participants could not have a stem cell transplant or CAR-T therapy. The goal was to find a safe and effective dose of maplirpacept when added to the other two drugs. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: maplirpacept (PF-07901801), tafasitamab, and lenalidomide
What this could lead to: If this combination works, it could offer a new treatment option for people with DLBCL who cannot have a stem cell transplant or CAR-T therapy.
What could go wrong: This is a very early, small trial (only 6 participants) that was terminated, so results are limited. The combination may cause serious side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Dong-A University Hospital

Busan, Pusan-kwangyǒkshi, 49201, South Korea
Lifespan Cancer Institute

Providence, Rhode Island, 02903, United States
Mary Bird Perkins Cancer Center

Baton Rouge, Louisiana, 70809, United States
Seoul National University Hospital

Seoul, Seoul-teukbyeolsi [seoul], 03080, South Korea
The Miriam Hospital

Providence, Rhode Island, 02906, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
Yamagata University Hospital

Yamagata, 990-9585, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.